Patent ID: 7939272

Claim:
A method of predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising: assessing the level of the biomarker HER3 or pHER3 expressed by a tumor cell; determining whether HER3 or pHER3 is expressed at a high or a low level compared to a reference tumor cell level, and predicting high sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor if high levels of biomarker HER3 or pHER3 expression are found, and low sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor if low levels of biomarker HER3 or pHER3 expression are found, wherein if HER3 is the biomarker assessed, the level of the HER3 expressed by a tumor cell is assessed by determining the level of HER3 protein.